Navigation Links
AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing
Date:11/19/2009

hold. This is exactly what we did with our Alzheimer's vaccination program and the outcome in the Phase I trials at this stage enabled us to make this decision earlier than we expected and to offer a booster vaccination to the AD02-treated patients. Finally, we can also redirect our resources which will now be available for our other vaccination programs." AFFiRiS AG can also invest all of the EUR 10 million, paid by licensing partner GSK Biologicals as a milestone payment for the positive completion of the Phase I studies, in the other R&D programs.

The vaccine development program of AFFiRiS is based on the company's AFFITOME(R) technology, which also delivered the vaccines tested so far. Also based on this technology are six other vaccination programs being developed by AFFiRiS AG, which target, among other indications, Parkinson's disease and atherosclerosis.

About AFFiRiS AG (status November 2009):

Based on proprietary patent positions, AFFiRiS has developed tailored peptide vaccines against Alzheimer's Disease, Parkinson's and four other diseases characterized by urgent medical requirement and attractive market volumes. Alzheimer's is the current lead indication and clinical Phase I trials have just been completed on two product candidates. AFFiRiS succeeded in attracting GlaxoSmithKline Biologicals as its licensing partner in October 2008. The contract contains provisions for (milestone-dependent) payments of up to EUR 430 million. Based on the successful completion of two clinical Phase I trials, a payment of EUR 10 million was made in October. AFFiRiS currently employs 60 highly-qualified staff at its premises on the St. Marx Campus in Vienna, Austria (http://www.affiris.com).


    Contact AFFiRiS AG:
    Mag. Agnes Meyer
    Karl-Farkas-Gasse 22
    T +43-1-798-15-75-3
    mailto:agnes.meyer@affiris.com
    '/>"/>
SOURCE AFFiRiS AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
2. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
3. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
4. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
5. Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
6. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
7. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 September 2009
8. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
9. Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
10. Bavarian Nordic A/S - Half Year Interim Report 2009
11. Arpida Reports Interim Results For Six Months to 30 June 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... A new report, commissioned by BioCrossroads and conducted by ... at Indiana,s capital market and ... time frames: 1993 to 2002 and 2003 to 2013.  ... investment growth.  The Life Science Innovation Capital in ... innovation dollars as well as an increase in life ...
(Date:10/30/2014)... of the key challenges in the development of quantum ... , In a paper published today (28 October) in ... show how to make a new type of flexibly ... such as high-precision sensors and specialised superfast computers, often ... the methods for trapping these tiny particles are hugely ...
(Date:10/27/2014)... October 27, 2014 Ryan Carfley , ... month to sit down with Bryan Hamilton, the publisher of ... to discuss talent in the Research Triangle region of North ... were highlighted at the roundtable include the role of ... significance of work/life balance and the unique role that Millennials ...
(Date:10/27/2014)... -- The Italian company Roadrunnerfoot has ... its artificial "lower limb", after the German giant ...      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ) , ... judgement has arrived: Roadrunnerfoot, the small Italian company ... prostheses with composite materials, has won against global ...
Breaking Biology Technology:New report shows Indiana's gains in life sciences innovation capital outpace the nation 2New report shows Indiana's gains in life sciences innovation capital outpace the nation 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 4New report shows Indiana's gains in life sciences innovation capital outpace the nation 5Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2
... BRUNSWICK, N.J. and NANJING, China, Sept. 3 ,Acesys ... combining the drug discovery expertise and project management,capabilities ... chemistry resources and,favorable cost structure of Acesys in ... alliance will encompass all,aspects of medicinal chemistry for ...
... strategic planner for an organization in the filter industry? ... Are you part of a filter company looking ... the growth segments in the filter and filtration markets. ... Place in Charlotte, NC, the American Filtration and Separations ...
... HOBOKEN, N.J. - Dr. Yong Shi of Stevens ... grant for his project titled "MEMS Umbrella-Shaped Actuator ... was approved on scientific/technical merit for three years ... the research is to design, fabricate and test ...
Cached Biology Technology:Acesys and Provid Announce Alliance for Medicinal Chemistry Services 2Filter Markets - Discover the Growth Segments 2Filter Markets - Discover the Growth Segments 3Dr. Yong Shi awarded NSF grant 2
(Date:10/31/2014)... Bugnyar and his team have been studying the ... Northern Austrian Alps for years. They observed that ... as grooming and playing. However, they also observed ... a third individual. Although in about 50 % ... broke up the two affiliating ravens, intervening can ...
(Date:10/30/2014)... When most animals begin life, cells immediately begin accepting ... organ. However, mammals, including humans, are special. The cells ... choice – to become the protective placenta or to ... critical first step that research from Michigan State University ... current issue of PLOS Genetics , ...
(Date:10/30/2014)... developed a suite of technologies that can be used ... applications in everything from search and rescue to service ... platform for computer-mediated communication between humans and dogs that ... behavioral signals and sending them clear and unambiguous cues ... of computer science at NC State and co-lead author ...
Breaking Biology News(10 mins):Identifying the source of stem cells 2New tech aims to improve communication between dogs and humans 2
... release is available in Spanish . ... However, human nutrition researchers agree that many questions remain about ... Studies led by Agricultural Research Service (ARS) molecular biologist Daniel ... Certain kinds of inflammation can increase risk of cancer ...
... is available in Spanish . Researchers ... the Clinical Hospital San Cecilio and the University Rey Juan ... patients with tension headache improves within 24 hours after receiving ... an increasing incidence in the population. This type of disorder ...
... The ,Geographic Chemicals in Groundwaters and Soils, event ... Marie Curie Research Training Network. This network, coordinated ... to highlight the environmental effect including the effect ... in groundwater and soils. Held today and tomorrow ...
Cached Biology News:Luteolin stars in study of healthful plant compounds 2University of Manchester academics at international conference on geographic chemicals 2
...
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
... are macroporous polystyrene beads for hydrophobic interaction ... for adsorbing organics of molecular weight less ... are useful for the adsorption of nonpolar ... the removal of detergents such as Triton ...
... Immunogen : Fusion protein corresponding ... of human Mi-2 Formulation: 0.7M ... 0.035% sodium azide, containing 30% ... by immunoblot on Hela nuclear ...
Biology Products: